DarioHealth Corp.
Close on Oct 19, 2026
- Market cap
- $41.95M
- P/E (TTM)
- 1.1
- Dividend yield
- –
About DarioHealth
Surgical & Medical Instruments & Apparatus, SIC 3841
Dario develops a digital health platform that combines proprietary hardware, artificial intelligence, and behavioral support to manage chronic conditions. Its offerings address health areas such as cardiometabolic care for diabetes and hypertension, weight management, musculoskeletal pain, and mental health issues including depression and anxiety. These solutions integrate connected medical devices, digital applications, personalized coaching, and virtual clinical care. The company serves individual consumers directly as well as institutional clients across several business segments, including medium-to-large employers, national and regional health plans, and global pharmaceutical manufacturers.
The company operates in the United States and selected international markets, providing its digital health programs globally in ten different languages. Its eligible user base spans millions of individuals, and its commercial accounts include more than one hundred and sixty employer customers. Dario distributes its solutions through direct sales teams, consultants, brokers, and channel partnerships with major health insurance organizations. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of DarioHealth's latest annual report, written by StockData.
Company profile
Company
- Legal name
- DarioHealth Corp.
- Headquarters
- New York, NY
- Address
- 322 W 57th St. #33b 10019
- Phone
- 972-4-770-6377
- Employees
- 160, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman, Tel Aviv, Israel
Stock & identifiers
- Ticker
- DRIO
- Exchange
- Nasdaq
- IPO date
- Mar 14, 2016
- Shares outstanding
- 10M, Aug 11, 2026
- Public float
- $27.98M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Aug 28, 2025; 1-for-20 reverse, Mar 17, 2020; 1-for-18 reverse, May 11, 2016; 1-for-5 reverse, Nov 14, 2014
- SEC CIK
- 1533998
- CUSIP
- 23725P308
- ISIN
- US23725P3082
- EIN
- 45-2973162
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Erez Raphael | Chief Executive Officer, Director | 456,326 |
| Lara Ann Sherman | Chief Operating Officer | 120,000 |
| Chen Franco-Yehuda | Chief Financial Officer | 125,000 |
| Steven Charles Nelson | President and CCO | 34,750 |
| Yoav Shaked | Director | 87,666 |
| Adam K. Stern | Director | 75,623 |
| Dennis M. McGrath | Director | 88,737 |
| Dennis Matheis | Director | 87,026 |
| Hila Karah | Director | 58,965 |
| John R. Palumbo | Director | 66,500 |
| Lawrence B. Leisure | Director | 32,900 |
| Jon H. Kaplan | Director | 111,574 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Erez Raphael | $1.96M | $1.68M | $5.24M | $46 | – |
| FY2023 Erez Raphael | $722.19K | $274.28K | $879.23K | $40 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 11, 2026, we had 160 full-time employees and five part-time employees.”
Corporate history
Events identified from SEC filings